USA - NASDAQ:TWST - US90184D1000 - Common Stock
The current stock price of TWST is 28.16 USD. In the past month the price increased by 0.97%. In the past year, price decreased by -40%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.68 | 405.55B | ||
AMGN | AMGEN INC | 13.7 | 160.87B | ||
GILD | GILEAD SCIENCES INC | 15.87 | 152.38B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 106.87B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.14B | ||
REGN | REGENERON PHARMACEUTICALS | 12.67 | 61.27B | ||
ARGX | ARGENX SE - ADR | 91.6 | 51.94B | ||
INSM | INSMED INC | N/A | 35.04B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.76B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
NTRA | NATERA INC | N/A | 24.94B | ||
BIIB | BIOGEN INC | 8.93 | 20.97B |
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 923 full-time employees. The company went IPO on 2018-10-31. The firm's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The company has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The firm also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The firm's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. The company has minority ownership in Atlas Data Storage, Inc.
TWIST BIOSCIENCE CORP
681 Gateway Blvd.
South San Francisco CALIFORNIA 94080 US
CEO: Emily M. Leproust
Employees: 923
Phone: 18007190671
The current stock price of TWST is 28.16 USD. The price decreased by -8.42% in the last trading session.
The exchange symbol of TWIST BIOSCIENCE CORP is TWST and it is listed on the Nasdaq exchange.
TWST stock is listed on the Nasdaq exchange.
16 analysts have analysed TWST and the average price target is 45.58 USD. This implies a price increase of 61.86% is expected in the next year compared to the current price of 28.16. Check the TWIST BIOSCIENCE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TWIST BIOSCIENCE CORP (TWST) has a market capitalization of 1.70B USD. This makes TWST a Small Cap stock.
TWIST BIOSCIENCE CORP (TWST) currently has 923 employees.
TWIST BIOSCIENCE CORP (TWST) has a support level at 25.31 and a resistance level at 31.05. Check the full technical report for a detailed analysis of TWST support and resistance levels.
The Revenue of TWIST BIOSCIENCE CORP (TWST) is expected to grow by 20.56% in the next year. Check the estimates tab for more information on the TWST EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TWST does not pay a dividend.
TWIST BIOSCIENCE CORP (TWST) will report earnings on 2025-11-17, after the market close.
TWIST BIOSCIENCE CORP (TWST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.25).
The outstanding short interest for TWIST BIOSCIENCE CORP (TWST) is 21.65% of its float. Check the ownership tab for more information on the TWST short interest.
ChartMill assigns a technical rating of 4 / 10 to TWST. When comparing the yearly performance of all stocks, TWST is a bad performer in the overall market: 91.95% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to TWST. TWST has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months TWST reported a non-GAAP Earnings per Share(EPS) of -2.25. The EPS increased by 41.1% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -13.24% | ||
ROE | -17.81% | ||
Debt/Equity | 0 |
16 analysts have analysed TWST and the average price target is 45.58 USD. This implies a price increase of 61.86% is expected in the next year compared to the current price of 28.16.
For the next year, analysts expect an EPS growth of 58.85% and a revenue growth 20.56% for TWST